We describe a 5-year-old girl with Ph(؉) CML who received a cord blood transplant in a second accelerated phase after a very early lymphoid blast crisis. She was induced into CR by ALL-directed chemotherapy and then maintained with IFN-␣2b together with weekly rotational chemotherapy. Nineteen months after diagnosis, her mother gave birth to an HLA-compatible sibling, whose cord blood was cryopreserved. The patient's second acceleration occurred 22 months after the CML diagnosis 1,2 This type of transplantation is clearly superior to conventional therapy and hence should be considered when treating any child with this disease; however, only a minority of patients have HLA-compatible related donors, and a patient belonging to an ethnic group that is not widely represented in the registries is even less likely than most patients to find a perfectly matched unrelated donor (MUD).
Allogeneic hematopoietic cell transplantation is at present the only potentially curative therapy in patients with CML. 1, 2 This type of transplantation is clearly superior to conventional therapy and hence should be considered when treating any child with this disease; however, only a minority of patients have HLA-compatible related donors, and a patient belonging to an ethnic group that is not widely represented in the registries is even less likely than most patients to find a perfectly matched unrelated donor (MUD). 3 Furthermore, marrow delivery can be difficult for centers not accredited by the international registries network. For children experiencing blast crisis who lack a related donor, three goals emerge -to return the disease to its chronic phase, to slow further disease progression and to explore the possibility of performing an allogeneic stem cell transplant. If the first two goals are met, the search for MUD can begin, and if the search is successful, a transplant can be performed. Alternatively, the patient's mother may opt to plan a pregnancy, which, assuming HLA compatibility of the fetus, will allow for the collection of cord blood for transplantation. We report a successful related cord blood transplant in a child with CML who had rapidly progressed to blast crisis.
Case report
A 5-year-old girl, the only child of young parents, was admitted in May 1995 with a 2-week history of low-grade fever, leg pain and swelling of the feet. Physical examination revealed inguinal, submaxillar and axillar lymph nodes, enlarged up to 2 cm, moderate hepatomegaly ϩ2 cm and redness, pain and swelling of the right ankle joint. No splenomegaly was present. Her CBC revealed Hb 98 g/l, platelets 533 ϫ 10 9 /l, WBC 72 ϫ 10 9 /l, myeloblasts 3%, promyelocytes 6%, myelocytes 6%, metamyelocytes 10%, bands 9%, segmented 50%, eosinophils 5%, basophils 7%, monocytes 1%, lymphocytes 3%. Bone marrow aspirate showed blast cells 5%, increased to 73% myeloid lineage with myeloblasts 9% and promyelocytes 4%. BM cytogenetics demonstrated Ph chromosome in 100% metaphases. A diagnosis of CML was made and, in the absence of a matched donor, hydroxyurea 50 mg/kg b.w. per day was initiated; however, the patient's clinical state continued to deteriorate, as indicated by her high fever, polyarthritis and splenic enlargement. One month later, 46% blast cells emerged in the peripheral blood which expressed TdT, CD10, CD19, CD22 and HLA DR, whereas T-lineage and myeloid markers were negative. This confirmed a B-lineage blast crisis of CML, and the patient began standard ALL induction therapy consisting of vincristine, prednisolone, daunorubicin and l-asparaginase. Blast cells cleared from the bone marrow after 2 weeks of therapy and chronic phase CML was restored on day 33. Further chemotherapy consisted of three 5-day 'blocks' according to a high-risk branch of the BFM-ALL-90 protocol which contains highdoses of MTX, dexamethasone, 6-thioguanine, CY, VP-16 and anthracyclines. 4 CNS prophylaxis consisted of seven intrathecal injections of MtX and Ara-C and cranial irradiation to 18 Gy. After the third cycle of chemotherapy, interferon-␣ 2b ('Intron A', Schering-Plough, Rathdrum, Ireland) 3 MU/m 2 s.c. 6 days per week was initiated together with rotational weekly chemotherapy involving pairs of drugs (VP-16, CY, VCR, Dexa, Ara-C, 6-MP, MTX) according to the modified St Jude CRH protocol for relapsed ALL. 5 This combined therapy was continued until the beginning of conditioning for cord blood transplantation. Thirteen months later, the blood and bone marrow appearances were compatible with complete hematological remission whereas BM karyotyping showed only minimal cytogenetic response (20% of Ph-negative metaphases). However, a brief interruption of IFN therapy immediately led to a prompt increase in the WBCs to 50 ϫ 10 9 /l. In February 1997, the patient's mother gave birth to a boy whose cord blood was harvested and cryopreserved with DMSO. The total volume of the sample was 115 ml, total cellularity 2.04 ϫ 10 9 , and CD34 ϩ cell content 3% of the NC. HLA-typing by serology showed HLA phenotype A2,A19 B5,B12 DRB1 04,DRB1 14 DQB1 05 in patient and sibling. Heteroduplex analysis of amplified DRB1 and DQB1 regions confirmed full DR B and DQ B match.
In April 1997, a second acceleration occurred with enlargement of the spleen, an increase in the platelet count to 963 ϫ 10 9 /l, an increase of basophils to 15% in the peripheral blood and an increase in the blasts to 9.6% on BM aspirate. The decision was made to proceed to cord blood transplantation.
The child was nursed in a laminar flow room. Antimicrobial prophylaxis consisted of oral ciprofloxacin, fluconazole, amphothericin B and amoxicillin. As the child was anti-CMV IgG positive gancyclovir 10 mg/kg b.w. i.v. per day was given on days Ϫ8 to Ϫ1 to prevent early CMV reactivation. The conditioning regimen consisted of busulfan p.o. 4 mg/kg in divided doses, administered on days Ϫ9, Ϫ8, Ϫ7 and Ϫ6 (total dose 16 mg/m 2 ), HD Ara-C 2 g/m 2 i.v. twice daily on days Ϫ5, Ϫ4 and Ϫ3 (total of six doses) and melfalan 140 mg/m 2 i.v. on day Ϫ2. To prevent GVHD, cyclosporin A was administered starting on day Ϫ1 at 3 mg/kg per day in two divided doses i.v. To prevent veno-occlusive disease of the liver (VOD), unfractionated heparin was administered at 100 U/kg per day via continious i.v. infusion. Piperacillin/tazobactam and vancomycin were administered starting on day 0. The dose of total nuclear cells infused was 0.85 ϫ 10 8 /kg, CD34 ϩ cells 1.8 ϫ 10 6 /kg, CFU-GM 1 ϫ 10 4 /kg. The post-transplant period was complicated by a fever of unknown origin and respiratory distress on day ϩ10, successfully managed with methylprednisolone 10 mg/kg day. G-CSF 6.5 g/kg s.c. day was administered from day ϩ18, but engraftment was delayed until day ϩ35. Bone marrow cytogenetics on day 38 displayed 46 XY in 100% metaphases. On day ϩ45, oliguria, jaundice, tender hepatomegaly and refractoriness to platelet transfusions occurred. The bilirubin peaked at 1000 mol/l on day ϩ65. A diagnosis of the VOD of the liver was made, managed with fluid restriction, diuretics and vigorous platelet transfusions. This resolved by day 90.
Prompted by deterioration of renal function and in an attempt to promote a GVL effect, CsA was abruptly stopped on day ϩ40. Acute, biopsy-proven grade II gastrointestinal GVHD occurred on day ϩ115 and subsided with methylprednisolone 2 mg/kg per day. At the time of writing, 23 months after cord blood transplantation, the patient is alive with a perfect performance status and no sign of chronic GVHD. The late post-transplant period has been marked by a constant leukocytosis of up to 28 ϫ 10 9 /l, but the differential count is normal. BM cytogenetics are repeatedly 46 XY. FISH for t(9;22)(q34;q11) and PCR for bcr/abl RNA have been negative on multiple occasions.
Discussion
Patients who experience blast crisis of CML have a very poor outlook, even if a BMT is performed. There are two reasons for treatment failure: increased procedure-related mortality and a high relapse rate. 6 The latter can theoretically be overcome through intensified conditioning and the use of cord blood as a source of stem cells. Immunological naivety 7 of cord blood lymphocytes decreases the probability of intractable GVHD, allowing the safe reduction of post-transplant immunosuppression. This less intensive and shortened immunosuppression permits lymphocytes to exert their antileukemic effect better, believed to be the primary mechanism of the curative potential of BMT for CML, as evidenced by the high rate of remissions induced by donor lymphocyte infusion for relapse of CML after BMT. 8 It has also been proven that rapid CsA withdrawal may result in reinduction of cytogenetic and molecular remission in the majority of patients with CML who relapse after allogeneic BMT. 9 The case we describe demonstrates that a reinforced conditioning regimen, together with very short immunosuppression, can effectively eliminate Ph(ϩ) hemopoiesis, even under highly unfavorable conditions, such as those present in the advanced phase of the diseasesecond acceleration after early lymphoid blast crisis. Nonetheless, the benefits of this approach are offset somewhat by the possibility of multiple, severe complications during conditioning and the risk of acute GVHD. In conclusion, the chronic nature of CML provides the pediatric hematologist with a unique opportunity to perform cord blood transplantation, and parents may plan a pregnancy that enables harvesting of cord blood. In the event of HLA compatibility, transplantation can be performed with minimal immunosuppression in order to induce a maximal GVL effect. Our experience demonstrates the feasibility of such an approach.
